A patient with lorlatinib secondary dyslipidemia was given oral resuvastatin combined with ezetimibe lipid-lowering drug treatment by the hospital outpatient doctor, and developed liver damage one month after the treatment. Clinical pharmacists evaluated in detail the treatment plans, changes in blood indicators before and after medication, and blood lipid control, searched the related literature, and considered that the patient’s liver damage was related to rosuvastatin. Clinical pharmacists suggested to discontinue rosuvastatin and switch to PCSK9 inhibitor one month later, and the doctor accepted the suggestion. After discontinuing medication for one month, the liver enzyme indicators of the patient returned to normal, and PCSK9 inhibitor was applied afterwards. Clinical pharmacists continuously monitored changes of the patient’s condition, and during a 6-month follow-up period, the blood lipid control met the standard with good tolerance. In this case, clinical pharmacists carried out medication analysis and pharmacological care of PCSK9 inhibitors applied to patients with dyslipidaemia secondary to loratini, analysed the correlation between PCSK9 and lung cancer through relevant literature sreening, observed and summarized the efficacy and safety of the drug to provide a reference for the clinical development of the scheme.

1.Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J].Chin Med J (Engl), 2022, 135(5): 584-590. DOI: 10.1097/CM9. 000000000 0002108.

2.Azelby CM, Sakamoto MR, Bowles DW. ROS1 targeted therapies: current status[J]. Curr Oncol Rep, 2021, 23(8): 94. DOI: 10.1007/s11912-021-01078-y.

3.Pirker R, Filipits M. From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer[J]. ESMO Open, 2019, 4(5): e000548. DOI: 10.1136/ esmoopen-2019-000548.

4.董懂, 黄意恒, 张亚杰, 等. 《中华医学会肺癌临床诊疗指南(2023版)》解读[J]. 中国胸心血管外科临床杂志, 2023, 30 (11): 1533-1538. [Dong D, Huang YH, Zhang YJ, et al. Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition): an interpretation[J]. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30 (11): 1533-1538.] DOI: 10.7507/1007-4848.202309018.

5.Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study[J]. Lancet Onco, 2018 19: 1654-1667. DOI: 10.1016/S1470-2045(18)30649-1.

6.Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer[J]. N Engl J Med, 2020, 383(21): 2018-2029. DOI: 10.1056/NEJMoa2027187.

7.Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial[J]. Lancet Oncol, 2017, 18(12): 1590-1599. DOI: 10.1016/S1470-2045(17)30680-0.

8.Bauer TM, Felip E, Solomon BJ, et al. Clinical management of adverse events associated with lorlatinib[J]. Oncologist, 2019, 24(8): 1103-1110. DOI: 10.1634/theoncologist.2018-0380.

9.Lu S, Zhou Q, Liu X, et al. Lorlatinib for previously treated ALK positive advanced NSCLC: primary efficacy and safety from a phase 2 study in People's Republic of China[J]. J Thorac Oncol, 2022, 17(6): 816-826. DOI: 10.1016/j.jtho.2022.02.014.

10.Alonso R, Cuevas A, Cafferata A. Diagnosis and management of statin intolerance[J]. J Atheroscler Thromb, 2019, 26(3): 207-215. DOI: 10.5551/jat.RV17030.

11.Mahboobnia K, Pirro M, Marini E, et al. PCSK9 and cancer: rethinking the link[J]. Biomed Pharmacother, 2021, 140: 111758. DOI: 10.1016/j.biopha.2021.111758.

12.中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中国循环杂志, 2023, 38(3): 237-271. DOI: 10.3969/j.issn.1000-3614.2023.03.001.

13.周清, 陆舜, 李勇, 等. 洛拉替尼特殊不良反应管理中国专家共识[J]. 中国肺癌杂志, 2022, 25(8): 555-566. [Zhou Q, Lu S, Li Y, et al. Chinese expert consensus on the management of specific adverse reactions to loratinib[J]. Chinese Journal of Lung Cancer, 2022, 25(8): 555-566.]DOI: 10.3779/j.issn.1009-3419.2022.101.39.

14.Solomon BJ, Bauer TM, Mok TS, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN stud[J]. Lancet Respir Med, 2023, 11 (4): 354-366. DOI: 10.1016/S2213-2600(22)00437-4.

15.Lu S, Zhou Q, Liu X, et al. Lorlatinib for previously treated ALK-positive advanced NSCLC: primary efficacy and safety from a phase 2 study in People's Republic of China[J]. J Thorac Oncol, 2022, 17(6): 816-826. DOI: 10.1016/j.jtho.2022.02.014.

16.Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer[J]. J Thorac Oncol, 2017, 12: 1611-1625. DOI: 10.1016/j.jtho.2017.08.002.

17.Verdura S, Encinar JA, Fernández-Arroyo S, et al. Silibinin suppresses the hyperlipidemic effects of the ALK-tyrosine kinase inhibitor lorlatinib in hepatic cells[J]. Int J Mol Sci, 2022, 23(17): 9986. DOI: 10.3390/ijms23179986.

18.McGee K, Stone NJ, Wadhwani S, et al. A possible hyperlipidemia mechanism, suffering from loratanil treatment of metastatic non-small cell lung cancer[J]. J Oncol Pharmacy Practice, 2021, 27: 2010-2013. DOI: 10.1177/10781552211004698.

19.孙伟, 霍艳明, 王辉奇. 他汀类药物的不良反应及对策 [J]. 中西医结合心脑血管病杂志, 2017, 15(11): 1339-1341. [Sun W, Huo YM, Wang HQ. Adverse reactions and countermeasures of statins[J]. Journal of Cardiovascular and Cerebrovascular Diseases of Chinese and Western Medicine, 2017, 15(11): 1339-1341.] DOI: 10.3969/j.issn.

20.Barata F, Aguiar C, Marques TR, et al. Monitoring and managing lorlatinib adverse events in the portuguese clinical setting: a position paper[J]. Drug Saf, 2021, 44(8): 825-834. DOI: 10.1007/s 40 264-021-01083-x.

21.Preiss D, Tobert JA, Hovingh GK, et al. Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC Focus Seminar[J]. J Am Coll Cardiol, 2020, 75(16): 1945-1955. DOI: 10.1016/j.jacc. 2019.11.072.

22.Ference BA, Cannon CP, Landmesser U, et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration[J]. Eur Heart J, 2018, 39(27): 2540-2545. DOI: 10.1093/eurheartj/ehx450.

23.Gouni-Berthold I, Schwarz J, Berthold HK. PCSK9 monoclonal antibodies: new developments and their relevance in a nucleic acid-based therapy era[J]. Curr Atheroscler Rep, 2022, 24(10): 779-790. DOI: 10.1007/s11883-022-01053-3.

24.Khairunnisa NI, Yamasaki F, Miyata Y, et al. The efficacy of PCSK9 inhibitors in treating hypercholesterolemia caused by lorlatinib: a report of two cases[J]. Clin Lung Cancer, 202, 24(5): e176-e178. DOI: 10.1016/j.cllc.2023.03.016.

25.Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)[J]. Circulation, 2018, 137(4): 338-350. DOI: 10.1161/CIRCULATIONAHA.117.032235.

26.Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial[J]. Am Heart J, 2014, 168(5): 682-689. DOI: 10.1016/j.ahj.2014.07.028.

27.Liu X, Bao X, Hu M, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer[J]. Nature, 2020, 588(7839): 693-698. DOI: 10.1038/s41586-020-2911-7.

28.Bonaventura A, Grossi F, Montecucco F. PCSK9 is a promising prognostic marker in patients with advanced NSCLC[J]. Cancer Immunol Immunother, 2020, 69(3): 491-492. DOI: 10.1007/s00262-020-02485-z.

29.Zhou T, Zhan J, Fang W, et al. Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)[J]. BMC Cancer, 2017, 17(1): 269. DOI: 10.1186/s12885-017-3239-z.

30.Zhou T, Zhan J, Fang W, et al. Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)[J]. BMC Cancer, 2017, 17(1): 269. DOI: 10.1186/s12885-017-3239-z.

31.Migita T, Ruiz S, Fornari A, et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer[J]. J Natl Cancer Inst, 2009, 101(7): 519-532. DOI: 10.1093/jnci/djp030.

32.Jiang L, Jiang S, Lin Y, et al. Combination of body mass index and oxidized low density lipoprotein receptor 1 in prognosis prediction of patients with squamous non-small cell lung cancer[J]. Oncotarget, 2015, 6(26): 22072-22080. DOI: 10.18632/ on cotarget.4299.

33.Hao Y, Yang YL, Wang YC, et al. Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome[J]. Int Heart J, 2022, 63(4): 669-677. DOI: 10.1536/ihj.22-052.

34.Seidah NG. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies[J]. Curr Pharm Des, 2013, 19(17): 3161-3172. DOI: 10.2174/13816128113199990313.

35.Schmidt AF, Pearce LS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease[J]. Cochrane Database Syst Rev, 2017, 4(4): CD011748. DOI: 10.1002/14651858.